J&J’s Solid Launches Lead Strong Pharma Segment Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.
You may also be interested in...
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
J&J’s Consumer Woes Finally Subside As Pharma Continues Strong
The multinational health care company reported significant growth in 2013 that largely was driven by its pharmaceutical division, but bolstered by the resurrection of its long-plagued consumer brands.